Genmab Geared Up To Launch Epkinly With AbbVie
As FDA Approves CD20xCD3 Bispecific For Lymphoma
Executive Summary
The Danish group, along with partner AbbVie, is all set for a commercial battle with Roche as Epkinly hits the US market for refractory diffuse large B-cell lymphoma a few weeks ahead of expected approval for the Swiss major’s same-in-class rival glofitamab.
You may also be interested in...
In Competitive DLBCL Setting, Pfizer Goes Old School With Adcetris
The ECHELON-3 trial in third-line diffuse large B-cell lymphoma showed positive topline results regardless of CD30 expression, and the drug maker intends to take the data to the FDA.
Genmab On The Hunt For Late-Stage Assets
The Danish biotech has dipped its toe into co-commercialization recently and is seeking more candidates that are getting closer to the market.
Genmab/AbbVie Look To Encroach On Roche’s Turf With Epkinly Follicular Lymphoma Results
The companies unveiled results showing a high overall response rate from the anti-CD20xCD3 bispecific as competition heats up between various players in the space.